Effects of Mindfulness Meditation in Virtual Reality on Craving and Smoking Cessation

NCT ID: NCT05766553

Last Updated: 2026-01-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-06-15

Study Completion Date

2026-12-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Investigators seek to propose a non-drug therapeutic alternative, namely a mindfulness meditation protocol based on virtual reality training in order to induce progressive modifications of various indicators of craving.

The study hypothesis is that the practice of mindfulness meditation in a virtual reality environment reduces the craving induced by cues and stress and therefore ultimately smoking relapse.

The main objective of the protocol will be to demonstrate that mindfulness meditation can reduce long-term relapse (continuous cessation (\> 30 days) of smoking cessation).

The participants will be randomized into two groups: the experimental group will perform six virtual reality sessions in a multisensory cabin at the rate of one session per week; the control group will be prescribed the gold standard treatment (nicotine patches and chewing gum).

Participants will be seen again at three and six months to assess whether or not there has been a smoking relapse.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tobacco Use Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Interventional Group

Patients in this arm will have 6 sessions of virtual reality in a pod (1 session per week).

Patients will then have a visit at day 90 and day 180.

Group Type EXPERIMENTAL

Virtual reality pod

Intervention Type OTHER

The first two sessions provide guided training in relaxation and mindfulness through immersion in a virtual forest environment for the first session, and in a virtual beach environment for the second. Sessions 3 and 4 present environments with addiction-related stimuli (Cues). The session 3 consists of a walk through the virtual street environment, buying a bottle of water from the store, and then ordering a coffee from a virtual bar. The session 4 takes place in a virtual party environment in an apartment: people smoke and drink alcohol in the living room, the session consists of sitting with them, then going to the kitchen to get a water bottle. Sessions 5 and 6 present stressful environments. Session 5 consists of a virtual parachute jump. The 6th session takes place in a virtual airplane environment, which will encounter turbulence.

Control group

Patients in this arm will receive the gold standard of treatment for tobacco cessation (nicotine patches and chewing gum) from day 0 (inclusion visit) to day 90.

Patients will then have a visit at day 90 and day 180.

Group Type ACTIVE_COMPARATOR

nicotine patches and chewing gum

Intervention Type OTHER

Participants in this group will be prescribed a Gold Standard smoking cessation treatment with nicotine patches adapted to their consumption and 4mg nicotine chewing gum for a period of 3 months.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Virtual reality pod

The first two sessions provide guided training in relaxation and mindfulness through immersion in a virtual forest environment for the first session, and in a virtual beach environment for the second. Sessions 3 and 4 present environments with addiction-related stimuli (Cues). The session 3 consists of a walk through the virtual street environment, buying a bottle of water from the store, and then ordering a coffee from a virtual bar. The session 4 takes place in a virtual party environment in an apartment: people smoke and drink alcohol in the living room, the session consists of sitting with them, then going to the kitchen to get a water bottle. Sessions 5 and 6 present stressful environments. Session 5 consists of a virtual parachute jump. The 6th session takes place in a virtual airplane environment, which will encounter turbulence.

Intervention Type OTHER

nicotine patches and chewing gum

Participants in this group will be prescribed a Gold Standard smoking cessation treatment with nicotine patches adapted to their consumption and 4mg nicotine chewing gum for a period of 3 months.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Any patient consuming 10 to 40 cigarettes per day
* Woman or man aged 18 to 75 inclusive
* Substance use disorder according to the DSM5 classification
* Benefit from social security or benefit from it through a third party in accordance with French law on research involving the human person
* Having signed the informed consent form after having received written information.

Exclusion Criteria

* Disabling cognitive disorders
* Patient under 18 or over 75 years old.
* Patient with a psychological disorder or a psychiatric pathology requiring specialized follow-up
* Patient with addiction to another product.
* Cardiological pathologies that could compromise the participation of patients, detected by an ECG (only for patients who will be randomized in the experimental group).
* Advanced pulmonary, renal, and hepatic diseases, or any unstable and serious medical conditions that could compromise the patient's participation in the study, subject to the judgment of the doctor
* Pregnant or breastfeeding woman
* Simultaneous participation in another trial
* Employee of the investigator or of the clinical trial site
* Patients protected by law
* Patients who do not speak the French language
* People not covered by state health insurance
* Patients who in the opinion of the investigator are unable to complete the questionnaires
* Patient claustrophobic or anxious about using the cabin
* Patient allergic to a molecule present in nicotine substitutes
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre Hospitalier Henri Laborit

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Cabinet Médical

Iteuil, , France

Site Status RECRUITING

Cabinet médical des Couronneries

Poitiers, , France

Site Status RECRUITING

Centre Hospitalier Henri Laborit

Poitiers, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Nematollah JAAFARI

Role: CONTACT

+33 5 16 52 61 18

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Marc Besnier, MD

Role: primary

Lakshmipriya LE BONHEUR, MD

Role: primary

Nemat Jaafari, PU-PH

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2022-A02004-39

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Provoked Craving Relief Study by NRT
NCT01476202 COMPLETED PHASE2
Effects of Nicotine in Tobacco Smokers
NCT03651869 COMPLETED PHASE1
The Use of TDCS for Vaping Reduction
NCT06885606 NOT_YET_RECRUITING NA